EP Patent

EP4089093A1 — Radiosynthesis of [18f] talazoparib

Assigned to Eberhard Karls Universitaet Tuebingen · Expires 2022-11-16 · 4y expired

What this patent protects

The present invention relates to the synthesis of Poly (ADP ribose) polymerase (PARP) inhibitors and particularly to the radiosynthesis of PARP 1 inhibitors, more particularly to the synthesis of [<sup>18</sup>F] talazoparib.

USPTO Abstract

The present invention relates to the synthesis of Poly (ADP ribose) polymerase (PARP) inhibitors and particularly to the radiosynthesis of PARP 1 inhibitors, more particularly to the synthesis of [<sup>18</sup>F] talazoparib.

Drugs covered by this patent

Patent Metadata

Patent number
EP4089093A1
Jurisdiction
EP
Classification
—
Expires
2022-11-16
Drug substance claim
No
Drug product claim
No
Assignee
Eberhard Karls Universitaet Tuebingen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.